Give Every Lu-177 PSMA Patient a Written Discharge Template
On Target · Issue 16•Week Ending November 6, 2026 Give
Commercial Momentum and Diagnostic Evidence Move Together
On Target · Issue 15•Week Ending October 30, 2026 Commercial
Radioligand Diversification, Not Just Consolidation
On Target · Issue 14•Week Ending October 23, 2026 Radioligand
Supply Chains Are Reorganizing Around Fewer, Larger Players
On Target · Issue 13•Week Ending October 16, 2026 Supply
PSMA-Targeted Care Is Diversifying on Both Ends
On Target · Issue 12•Week Ending October 9, 2026 PSMA-Targeted
Reimbursement and Regulation Catch Up With PSMA PET
On Target · Issue 11•Week Ending October 2, 2026 Reimbursement
Consolidation Moves From the Agent to the Isotope Supply
On Target · Issue 10•Week Ending September 25, 2026 Consolidation
Two FDA Approvals and a $1 Billion Bet on Manufacturing
On Target · Issue 9•Week Ending September 18, 2026 Two
PSMA PET Moves Earlier as the Target Becomes a Platform
On Target · Issue 8•Week Ending September 11, 2026 PSMA
Three Publications Refine How Much Lutetium Is Enough
On Target · Issue 7•Week Ending September 4, 2026 Three